Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2
Authors
Keywords
-
Journal
INTEGRATIVE CANCER THERAPIES
Volume -, Issue -, Pages 153473541879486
Publisher
SAGE Publications
Online
2018-09-08
DOI
10.1177/1534735418794867
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Is autoimmunity the Achilles' heel of cancer immunotherapy?
- (2017) Carl H June et al. NATURE MEDICINE
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation
- (2016) Matthew S. Davids et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy
- (2015) Edward J Wyluda et al. CANCER BIOLOGY & THERAPY
- Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency
- (2015) Tibor Bakacs et al. IMMUNOBIOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulatory T cells in the immunotherapy of melanoma
- (2015) Zhengxiao Ouyang et al. TUMOR BIOLOGY
- Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma
- (2015) G. de Velasco et al. Cancer Immunology Research
- Vaccines versus immunotherapy: Overview of approaches in deciding between options
- (2015) Angus G Dalgleish Human Vaccines & Immunotherapeutics
- Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
- (2014) R. W. Joseph et al. Cancer Immunology Research
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1
- (2013) Jörg B. Engel et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation
- (2013) Rainer Storb et al. JOURNAL OF CLINICAL ONCOLOGY
- Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity
- (2013) Shimon Slavin et al. PHARMACOLOGICAL RESEARCH
- Rare Cancer Successes Spawn 'Exceptional' Research Efforts
- (2013) J. Kaiser SCIENCE
- Temperature Matters! And Why It Should Matter to Tumor Immunologists
- (2013) E. A. Repasky et al. Cancer Immunology Research
- Old and new facts about hyperthermia-induced modulations of the immune system
- (2012) Benjamin Frey et al. INTERNATIONAL JOURNAL OF HYPERTHERMIA
- Pharmacological modulation of GITRL/GITR system: therapeutic perspectives
- (2011) Giuseppe Nocentini et al. BRITISH JOURNAL OF PHARMACOLOGY
- The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy
- (2011) T. Fu et al. CANCER RESEARCH
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
- (2010) B. C. Carthon et al. CLINICAL CANCER RESEARCH
- Anti-CTLA-4 therapy results in higher CD4+ICOShiT cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues
- (2009) Hong Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now